



Medicaid Select/HARP Updates

Effective September 15, 2021

The following drug products were reviewed and acted upon by the CDPHP Pharmacy and Therapeutics Committee for Medicaid Select/HARP.

Drug	Previous Coverage	Recommended Coverage
Aduhelm™ (aducanumab-avwa) intravenous injection	New to market	Not medically necessary- (refer to CDPHP policy, Pharmaceutical Treatment of Alzheimer's Disease)
aripiprazole oral solution	Prior authorization	Covered, QL
asenapine maleate sublingual tablets (generic of Saphris)	Prior authorization	Covered, QL, Prior authorization for patients less than 10 years of age only
Azstarys™ (serdexmethylphenidate/dexmethylphenidate)	New to market	Non-formulary
Brexafemme® (ibrexafungerp) tablets	New to market	Non-formulary
Emgality® (galcanezumab) injection	Non-formulary	Prior authorization
Empaveli™ (pegcetacoplan) subcutaneous injection	New to market	Prior authorization
febuxostat oral tablets (generic for Uloric)	Non-formulary	Covered
fosfomycin powder (generic for Monurol)	Non-formulary	Covered, QL
Jemperli® (dostarlimab-gxly) intravenous injection	New to market	Medical, Prior authorization
Kloxxado™ (naloxone)	New to market	Non-formulary
Lumakras™ (sotorasib) oral tablets	New to market	Prior authorization
Makena® (hydroxyprogesterone caproate) injection	Non-formulary	Prior authorization
modafinil oral tablets	Non-formulary	Prior authorization, QL
Myfembree® (relugolix/estradiol/norethindrone) oral tablets	New to market	Non-formulary
Neupogen® (filgrastim)	Prior authorization	Non-formulary
paliperidone extended release oral tablets (generic for Invega)	Prior authorization	Covered, QL, Prior authorization for patients less than 12 years of age only
Rybrevant™ (amivantamab-vmjw) intravenous injection	New to market	Medical, Prior authorization
Sunosi™ (solriamfetol) oral tablets	Non-formulary	Prior authorization, QL
Truselqi™ (infigratinib) oral capsules	New to market	Prior authorization
Wakix® (pitolisant) oral tablets	Non-formulary	Prior authorization, QL
Wegovy™ (semaglutide)	New to market	Excluded by statute
Zynlonta™ (loncastuximab tesirine-lpyl) intravenous injection	New to market	Medical benefit, Prior authorization